Summary Natural killer (NK) cell activity and lymphokine activated killer (LAK) cell cytotoxicity were measured in patients receiving recombinant interleukin 2 (rIL-2) and flavone acetic acid (FAA) for treatment of progressing metastatic melanoma. NK activity was increased in 23 of 26 patients and LAK activity induced in 13 of 26 patients. However, levels of cytotoxicity in the present study were not significantly greater than a previous study using rIL-2 alone. LAK cell precursors demonstrated by in vitro incubation of pretreatment lymphocytes with IL-2 and subsequent cytotoxicity were no different in the patients compared to normal controls. Analysis of cell surface phenotypes failed to reveal any significant changes in the cell populations examined, including IL-2R and Leu 19. Although five patients had tumour response, one being complete, there was no correlation with the immunological parameters examined.
Several studies have shown that the administration of interleukin 2, either alone or in conjunction with broadly cytotoxic lymphokine activated killer cells (LAK) generated by in vitro co-culture with IL-2 have resulted in tumour regression in a range of established human tumours including melanoma (Rosenberg et al., 1987; Rosenberg, 1988; West et al., 1987; Hank et al., 1988) . This combined adoptive immunotherapy is, however, expensive and labour intensive, and toxicity is severe when high doses of IL-2 are used. In our previous phase I/II clinical trial of intrasplenic and intravenous rIL-2 less toxicity was achieved and partial clinical responses were observed in 15% of patients with progressing advanced melanoma (Thatcher et al., 1989) . These encouraging results stimulated interest in using rIL-2 in combination with other biological response modifiers or with chemotherapeutic drugs in the hope that better clinical responses could be achieved.
Flavone acetic acid (FAA) is a synthetic flavonoid found to have an antitumour effect against a spectrum of murine solid tumours and to augment natural killer cell activity in spleen and other tissues in normal mice (Finlay et al., 1988; Zaharko et al., 1986; Ching & Baguley, 1987) . This suggested that FAA may act as a biological response modifier as well as functioning as a chemotherapeutic drug. NK cells have been shown to be the major effector cell population contributing to the generation of LAK activity by rIL-2 (Itoh et al., 1985; Ferrini et al., 1987; Herberman et al., 1987) . Preliminary studies by showed that FAA synergised with rIL-2 in the treatment of murine renal cancer. Further studies showed that this synergy was due to augmentation of natural killer cell activity, induction of IFN ct/p and induction of long lasting tumour immunity (Hornung et al., 1988a, b) .
On the basis of these properties of FAA, a phase II clinical trial of FAA in combination with intrasplenic and intravenous rIL-2 was initiated in patients with progressing malignant melanoma and in this report the immunological responses that resulted from this treatment are described. without local radiotherapy, although no patients had received anti-tumour treatment 4 weeks before entry into the study. Further clinical details from these patients are described elsewhere (Thatcher et al., 1990) .
Interleukin-2/flavone acetic acid administration Recombinant IL-2 (kindly supplied by Eurocetus BV, Amsterdam) was administered as described previously by Thatcher et al. (1989) . Briefly, the initial dose (intrasplenic) was followed 4 h later by intravenous administration followed by three alternate day i.v. doses. A maximum of three such courses was given at 21-day intervals after the FAA administration. The doses given (11 x 106 Cetus units mr2) were taken from the preceding phase I/II study of rIL-2 alone (Thatcher et al., 1989) Cytotoxic activity of PBMC in patients receiving FAA and rIL-2 treatment NK activity Ten of the 26 patients studied showed positive cytotoxicity (greater than 10% lysis) against the cultured K562 cell line before treatment with values ranging from 11 to 59%. In 23/26 patients significant increases in NK activity were observed while receiving FAA/IL-2 treatment, ranging from 2 to 20 times increase in cytotoxicity or from 12 to 91% lysis. However, no specific trends could be determined in subgroups of patients divided by their responses to treatment (progression, stable or response). This is illustrated for four patients in Figure 1 . One of the patients whose disease progressed (no. 22) showed augmented NK activity after the second course of treatment, while another patient (no. 3) showed similar levels of NK activity after the first two treatment cycles. The patient who had a complete response (no. 32) showed a dramatic increase in NK activity 14 days after the commencement of the first treatment cycle, which was not repeated after the second or third cycle. This graph also highlights the common feature to all the patients in this study; that the NK activity undergoes considerable fluctuation. LAK activity Only five of the 26 patients examined showed low levels of pre-treatment cytotoxity with Mel-I (LAK sensitive) targets with values ranging from 13 to 16% lysis. In general, the cytotoxic activities were lower than those for K562 targets (see Table I ). LAK cytolytic activity was observed, however, in 13 patients over the treatment period, with values ranging from II to 55%, indicating an increase in activity from 2 to 22 times. The Daudi (LAK sensitive) cell line was also used to investigate cytotoxic effects in seven patients. Values were similar to the Mel-i results. The most interesting finding, which seemed to parallel both the K562 and Mel-i results, was that of a dramatic increase in cytotoxicity two weeks after the first course of FAA/IL-2 in the patient who underwent a complete response (see Figure 2) . Indeed, the value for the Daudi cells was 99% (data not shown), the highest value seen throughout these experiments. The increases in LAK activity followed a similar time course to that of NK activity with a peak during the first or second weeks after FAA/IL-2 administration. Three patients who had samples collected immediately before and 1 and 2 h after IL-2 administration, showed that a decrease in LAK activity occurred within 1 h of IL-2 administration (data not shown). However, in two of the three the pre-treatment cytotoxicity values were less than 10%.
LAK cell precursors
Pre-treatment PBMCs from 20 patients were stimulated with 200 IU m-' rIL-2 in vitro for 5 days and their NK and LAK cell lytic activity were assayed and compared with four normal subjects. There was no difference in the cytotoxicities assayed against K562, the NK sensitive cell line, but higher cytotoxic values were obtained against Mel-and Daudi targets in the patient group compared to controls (Table II) . The inducibility of LAK activity in vitro was determined on day 7 after the first week of FAA and rIL-2 treatment in 13 patients. In nine patients there was augmentation of cytotoxic capacity of PBMCs induced by IL-2 in vitro against the Mel-i target, the highest increase from 41 to 79%. There were small increases up to 10% cytotoxicity observed against K562 in three patients after week of treatment.
Of the patients PBMC stimulated with rIL-2 in vitro, there (Itoh et al., 1985) . Any agent augmenting NK activity may therefore expect to synergise with the action of IL-2. FAA has been shown to have high anti-tumour activity and a possible host mediated mechanism of toxicity including augmentation of NK cell activity (Ching & Baguley, 1987; cancer. In our previous study of rIL-2 alone (Ghosh et al., 1989) , increased NK activity was observed in 16 of 20 patients while on treatment. showed maximal NK cell activity in the peripheral blood of mice at 48 h, which persisted for 6 days after FAA administration. Administration of IL-2 with FAA augmented systemic NK activity in renca tumour bearing mice 3-5-fold over that obtained with FAA or rIL-2 alone. A significant increase of NK activity with the combined treatment was not observed in the current patients when compared with the previous study of rIL-2 alone (Ghosh et al., 1989) , although the median levels of cytotoxicity were slightly higher. Again LAK activity was induced in 50% of patients and compares with 45% of patients in the previous IL-2 study. However, levels of cytotoxicity were not significantly greater than in the previous study.
Murine models have shown that there is a dose response to FAA for NK cell activation (Ching & Baguley, 1987) and that lower doses may be more effective than high doses at enhancing NK activity. As the FAA dose used in the study is considered to be the highest that was clinically tolerable, it may not have been the optimal dose to maximise its immunological effects. The timing of FAA and administration of rIL-2 may also be important in achieving their synergistic effect and the optimal conditions still need to be determined.
An anti-tumour effect may not be reflected in peripheral blood NK activity and it may be more relevant to examine the tumour infiltrating lymphocytes. Activated lymphocytes have been observed at the site of tumours and can be expanded in vitro with rIL-2 to produce both LAK cells and specific T cell responses (Anderson et al., 1988; Ettinghausen et al., 1985a,b) . However, it would be necessary to obtain tumour specimens before and after treatment to analyse the TILs effectively, although this approach has practical limitations.
The mode of action of FAA and rIL-2 in the treatment of murine renal cancer has been investigated Hornung et al., 1988a,b (Wiltrout & Hornung, 1988b Although animal models have indicated that combined FAA and rIL-2 administration have a greatly enhanced antitumour effect than either agent alone, the present clinical study showed only a slightly improved response rate compared to rIL-2 alone. This highlights the difficulty in translation of pre-clinical animal experimental trials into clinical treatment of patients. The patients were all capable of responding to IL-2 as shown by in vitro incubation of pretreatment lymphocytes with IL-2. A lack of response is therefore not due to lack of LAK cell precursors, although it was not possible to test cytotoxicity against autologus tumour. There was no significant correlation between clinical outcome and NK or LAK cell induction, although the patient with the highest NK value did show a complete response. Further immunological clinical studies involving IL-2 in combination with other cytokines are required.
